Compare DoorDash Inc (DASH) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Moderna, Inc. — how do they compare? DoorDash Inc trades at $188.64 (market cap $81.82B), while Moderna, Inc. trades at $67.13 (market cap $26.76B). The key difference: DoorDash Inc is far larger — about 3.1× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| DASH | MRNA | |
|---|---|---|
Market Cap | $81.82B | $26.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $81.80 |
52-Week Low | $146.60 | $22.36 |
Enterprise Value | $79.58B | $22.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $189.57, down 1.17% on the day, with a bullish technical outlook supported by moving averages and key resistance near $200. The company reported strong revenue growth to $13.72B in 2025 and achieved profitability with a net income margin of 6.81%. Recent partnerships, such as with Hungry Howie's and Urban Outfitters, highlight ongoing expansion in digital commerce and loyalty programs.
The stock presents a growth opportunity with a consensus price target of $237.92, implying 25% upside, but faces risks from intense competition and high valuation multiples. Earnings momentum is mixed, with a recent beat in Q1 2026 but misses in prior quarters. Investors should weigh robust cash flow generation against elevated P/E and EV/EBITDA ratios for a balanced view.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
